Aptevo files prospectus for resale of over 6.4 million warrant shares
The Seattle biotech registered shares tied to an August 12, 2026 private placement and warrant inducement, as its stock traded at $2.60 on Nasdaq.
Aptevo Therapeutics Inc. filed a prospectus dated September 3, 2026, covering the resale of up to 6,444,858 shares of common stock issuable upon exercise of pre-funded warrants, common warrants, and inducement warrants. The registration covers pre-funded warrants for up to 861,708 shares, common warrants for up to 4,308,540 shares, and inducement warrants for up to 1,274,610 shares issued to holders of the company's existing warrants.1
The pre-funded warrants and common warrants were issued in a private placement under a Securities Purchase Agreement dated August 12, 2026, while the inducement warrants were issued pursuant to Warrant Inducement and Reload Letters of the same date.1 On that date the company entered inducement letters with holders of warrants issued in June 2025, April 2025, and December 2024, under which those holders agreed to exercise existing warrants for up to 254,922 shares at a reduced price of $4.03 per share, and Aptevo issued inducement warrants for up to 1,274,610 shares at the same $4.03 exercise price.1 The company said it received approximately $4.5 million in gross proceeds from the inducement and concurrent private placement.1
Aptevo will not receive any proceeds from the resale of shares by the selling stockholders.1 Common stock trades on the Nasdaq Capital Market under the symbol APVO, and the last reported sale price on September 2, 2026 was $2.60 per share.1
The offering covers up to 6,444,858 shares, consisting of the pre-funded warrant shares, common warrant shares, and inducement warrant shares, against 1,810,215 shares of common stock outstanding prior to the offering, including 254,922 shares issued upon exercise of the existing warrants.1
Under a related Registration Rights Agreement dated August 12, 2026, the company agreed to file a registration statement to cover the resale of the warrant shares as soon as practicable, and in any event by August 22, 2026, and to seek effectiveness by September 26, 2026, or October 26, 2026 if the SEC conducts a full review.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.